The results showed that VIM (p = 0.0076) and KRT18 (p = 0.0196) were significantly upregulated in CIS-treated AS compared to untreated-AS (control), while CDH1 (p = 0.0116), CDH2 (p = 0.0005), KRT19 (p = 0.0248), and GATA6 (p = 0.0389) were decreased (Figure 5A). The gene discussed is KRT18; the disease is in situ carcinoma.